How FAI creates focal cartilage damage in the hip

Pain in the front of the hip — a deep ache in the groin that sharpens when sitting for long periods, climbing stairs, or drawing the knee towards the chest — is often the first sign that something structural is wrong inside the joint. For many patients, that something is femoroacetabular impingement, or FAI.

The hip is a ball-and-socket joint, and FAI arises when the geometry of those two surfaces does not quite fit together correctly. A cam lesion is an abnormal bony prominence on the femoral head (the ball), making it slightly out-of-round; a pincer lesion is an over-coverage of the acetabulum (the socket) that causes the rim to reach too far over the ball. Many patients have both. During everyday movements — particularly hip flexion and internal rotation — these bony abnormalities create abnormal contact inside the joint, generating concentrated mechanical shear at precisely the point where the acetabular rim meets the femoral head.

Over months and years, that repeated friction progressively strips away the articular cartilage lining the joint. Because the force is localised, the damage tends to be focal rather than uniform: a discrete patch — typically Grade III or IV cartilage loss — surrounded by cartilage that remains relatively intact. This matters clinically, because a joint with a focal defect alongside preserved surrounding tissue is a fundamentally different problem from a joint with global wear.

Articular cartilage has no blood supply of its own. Without the vessels, inflammatory cells, and progenitor cells that blood delivers, the tissue has very limited capacity to repair itself after injury. Once a focal chondral defect forms, it is unlikely to heal spontaneously — and the abnormal loading that caused it may continue to enlarge the affected area if left unaddressed.

Patients may notice groin pain, a catching or clicking sensation during hip movement, and stiffness first thing in the morning or after periods of inactivity. These symptoms can persist even after the bony impingement has been corrected, because the cartilage damage it caused remains.

Why the hip joint cannot repair cartilage on its own

Chondrocytes — the cells responsible for maintaining cartilage matrix — have no direct blood supply to sustain them. Instead they depend entirely on slow diffusion from synovial fluid: nutrients and signalling molecules seep inward, waste products seep out, across distances of less than a millimetre. In healthy cartilage of normal thickness, this arrangement is just sufficient. Once a defect deepens to Grade III or IV — cartilage thinned to, or exposing, the underlying subchondral bone — the cells at the defect margin are too far from the fluid surface, and diffusion alone cannot deliver the repair signals a rebuilding response would require.

The defect itself offers no reliable substitute. Subchondral bone exposed at the base of a Grade IV lesion may bleed transiently, sometimes producing a weak fibrocartilage patch; but fibrocartilage is mechanically inferior to the native hyaline tissue it replaces and rarely persists under repeated hip loading. More often, continued mechanical stress causes the defect edges to fray progressively, widening the affected area and increasing the risk of progression towards widespread hip osteoarthritis.

Beyond a certain defect size, even the modest diffusion pathway closes off — the lesion is simply too large for surrounding cells to bridge. At that point, biology alone has no mechanism to restart repair from within.

An injectable collagen scaffold is one way to bring a repair-friendly environment directly into the defect — providing the structural matrix and cellular signals that the hip's own biology cannot generate.

What ChondroFiller does inside the hip joint

ChondroFiller Liquid is a CE-marked Class III medical device: a Type I collagen extracted from rat-tail tendon using a weak-acid process that preserves the collagen's natural cross-linking structures, allowing it to self-assemble into a physiologically coherent fibril network once it enters the joint.

Injected under ultrasound guidance into the hip joint, the liquid gels within minutes at body temperature, filling the defect and forming a three-dimensional matrix that bonds to the surrounding cartilage. What happens next is a process called acellular matrix-induced chondrogenesis — in plain terms, the scaffold recruits the patient's own cells to do the repair work. Mesenchymal progenitor cells from the synovium and subchondral bone migrate chemotactically into the scaffold, drawn by the signals the collagen matrix presents. Over subsequent weeks and months, those recruited cells mature progressively toward a chondrocyte-like phenotype, laying down cartilage-like tissue within the defect. As that host tissue forms, the scaffold degrades and is replaced — the biological matrix the hip joint is provided with becomes, in time, the hip joint's own.

The goal is to support the body's own repair processes within a defect that cannot otherwise heal without intervention. This is meaningfully different from viscosupplementation with hyaluronic acid, which acts as a transient lubricant cleared from the joint within weeks and has no structural repair effect. ChondroFiller is a biological scaffold the hip joint can populate, integrate, and remodel — a distinction that matters when the underlying problem is tissue loss rather than lubrication deficit.

The outpatient injection pathway at Lincolnshire Hip

For patients considering ChondroFiller at Lincolnshire Hip, the practical reality of the appointment is considerably simpler than the biology suggests.

The collagen scaffold is placed using ultrasound-guided injection — a technique that allows precise, image-guided placement of the material directly into the identified focal defect within the hip joint, without a surgical incision, without general anaesthetic, and without an overnight stay. The entire appointment takes place in a clinic setting; patients arrive and leave the same day.

Before any injection is offered, Professor Paul Lee — who introduced ChondroFiller injection to the UK — conducts a pre-treatment assessment to establish whether the extent and location of a patient's hip cartilage loss make them a suitable candidate for this pathway. Not every focal defect will be appropriate, and that assessment is the starting point.

Clinics are held in Grantham and Sleaford, making the pathway accessible to patients across Lincolnshire and the wider East Midlands without the need to travel to a specialist centre in London. ChondroFiller hip injection is listed at £2,995 per injection, inclusive of the collagen matrix dose, the ultrasound-guided procedure, and a local follow-up appointment.

Lincolnshire Hip accepts patients without referral for hip assessment.

What outcomes patients can realistically expect

The most widely cited functional outcome measure for this treatment is the modified Harris Hip Score (mHHS). Clinical data show an approximate 30-point improvement in mHHS at 12 months in treated patients — a gain considered clinically meaningful for a hip preservation intervention. MRI-based MOCART scores, which assess the quality of cartilage fill within the treated defect, have ranged from 70 to 87 in reported series, suggesting meaningful structural change rather than simple symptom masking.

On safety, the published figures are reassuring. The reported complication rate is approximately zero, and reoperation rates in the region of 3–8% are substantially lower than published figures for microfracture (up to 41%) or two-stage cell therapies such as ACI and MACI, which carry complication rates up to 17% and reoperation rates up to 37%.

Where the evidence is thinner is in hip-specific, long-term data. Most comparative clinical evidence comes from combined-joint studies or cohorts weighted towards other joints. Hip-specific trial data beyond five years remain limited; if that length of follow-up matters to your decision, it is a reasonable question to raise at consultation, where individual circumstances can be weighed against what is currently known.

ChondroFiller injection is not a treatment for advanced hip osteoarthritis affecting the whole joint surface. Its role is hip preservation — supporting the body's own repair processes in suitable patients with focal cartilage defects, with the aim of slowing deterioration and, where possible, deferring the point at which surgical escalation becomes necessary.

Who is a suitable candidate for this injection

Identifying whether this injection pathway is worth pursuing comes down to a few specific clinical variables rather than age or symptom severity alone.

The treatment is designed for patients with confirmed focal Grade III or IV cartilage defects — typically identified on MRI — where the damage is localised rather than spread across the full joint surface. FAI-related lesions at the acetabular rim or femoral head are a recognised indication. Where cam or pincer morphology is contributing to the ongoing damage, a pre-treatment assessment will establish whether the underlying bony abnormality requires separate management alongside or before the collagen scaffold injection.

There are honest limits to who benefits. Patients with advanced osteoarthritis, significant joint space narrowing on imaging, or substantial subchondral bone loss are generally not suitable candidates for this pathway. In those cases, the more appropriate conversation tends to be about hip replacement assessment rather than cartilage preservation.

Age alone does not exclude a patient in principle. Because the scaffold works by recruiting the body's own progenitor cells from surrounding tissue, biological response is expected to be stronger where adequate cell activity remains — an individual factor that forms part of the pre-treatment clinical assessment rather than a rule applied by number.

Lincolnshire Hip accepts patients without referral. Clinics are held in Grantham and Sleaford, and an initial consultation involves imaging review and clinical examination to determine individual suitability. For many patients, that appointment is less a formality than the moment a realistic picture of what the hip still has to work with — and what treatment it can meaningfully respond to — becomes clear.

1. [1] Hip arthroscopy. https://en.wikipedia.org/?curid=31963181 https://en.wikipedia.org/?curid=31963181